Omnia Health is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Elevating the clinical laboratory's role in healthcare transformation

Article-Elevating the clinical laboratory's role in healthcare transformation

Interview with Dr Ismail A Bakhsh, Consultant Clinical Scientist, Director of Ancillary Services, National Medical Care, Saudi Arabia

The clinical laboratory has an essential role in all aspects of life and the diagnosis process starts early on in medical examination through blood testing or non-invasive testing. It plays an important role in any clinical decision and will have a 30 to 100 per cent impact based on the diagnosis itself and the continuity and outcome of the medical condition, according to Dr Ismail A Bakhsh, Consultant Clinical Scientist, Director of Ancillary Services, National Medical Care.

Today, healthcare systems are moving to become Accountable Care Organizations (ACO). Laboratory services are an integral part to the success of any healthcare system and can contribute a great deal to the success of the ACO model that aims to improve patient outcomes and population health management while keeping costs at a minimum.

At Global Health Exhibition, Dr Bakhsh will be discussing ACO’s and the laboratory’s integral contribution to the success of any healthcare transformation model.

He describes an ACO model as different organisations within a healthcare system working together to improve the health of their assigned local population through integrating the services to manage the causes of illnesses. Those groups of doctors, hospitals, and/or other healthcare providers must work together with a single goal of giving better care at a lower cost and this includes laboratory services.

Dr Bakhsh explained: “ACO is a relatively new concept and highlights the shift in the way we are serving and catering for our patients and clients. ACO’s will depend a lot on the laboratory because, for example, in certain chronic diseases such as diabetes, a diabetic patient will need to visit the doctor every two to three months and the visit will not be complete if they have not done any blood tests.”

ACOs have been created to push the industry away from fee-for-service towards value-based care through care coordination and a shared savings payment model. Effective contribution of any clinical laboratory services to ACO depends on the insurance of the effectiveness of five laboratory strategies. These include:

  1. Outreach services: The capacity to extend beyond the institute for wide coverage.
  2. Electronic connectivity: For example, easily requesting /ordering laboratory tests and accessing tests results remotely and freely.
  3. Lean processes: Better time utilisation, reduced errors, etc.
  4. Utilisation Management: Effective utilisation management plays a crucial role in decreasing costs without lowering quality.
  5. Aligning with the bigger picture: Laboratory data and resources play an important role clinically and for ACO planning and execution.

Impact of COVID-19 on laboratories

Several areas have been impacted due to COVID-19, stressed Dr Bakhsh. One has been the psychological impact of isolation and quarantine and how people are behaving because of it. Second, has been the financial impact due to drastic job losses, and third has been a shift in the environment of the laboratories due to the increased demand for COVID-19 testing.

“According to recent findings, there has been a reduction in about 14 per cent in the global laboratory industry, but there has also been a positive impact as the development of testing in such a short time was enhanced. So, we have seen a lot of development and enhancement in connectivity, communication, and digitalisation, among other areas,” he highlighted.

Additionally, technology has had a major impact on the day-to-day operations of the laboratory. Dr Bakhsh said that in his organisation, due to COVID-19, there was an increase in home visits, daily consultation, and telecommunication, for medical concerns.

“There has been a shift from face-to-face and physical communication, whether in the medical field or managerial roles,” he said. “Also, there been an increased use of artificial intelligence (AI) and I think it is a developing area, especially in centralising data. Moreover, AI is driven by the private sector, which more flexible and can see the return on investment.”

He concluded: “The message that I want to emphasise on is that ACO is all about the patient and how healthcare organisations should focus on providing high-quality, safe and cost-effective services.”


Dr Bakhsh will be speaking at the ‘Leaders Session: Transformation to ACO: How can the lab help?’ on December 7 at 6pm at the Global Health Exhibition.

He has over 25 years of experience in diagnostic, therapeutic laboratories and executive management. He is skilled in Epidemiology, Medical Devices, Oncology, Haematology, and Healthcare Information Technology (HIT) and also holds an MBA. His PhD, from the University of London, is focused on Haematology and Cellular Therapy.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.